Document is current
Any future updates will be listed below
-
Authors
Popper, Valentin
Spurny-Dworak, Benjamin
Unterholzner, Jakob
Reed, Murray
Wechsler, Theresa
Kautzky, Alexander
Stöhrmann, Peter
Klöbl, Manfred
Mühlberger, Andreas
Frey, Richard
Rujescu, Dan
Lanzenberger, Rupert
Vanicek, Thomas
-
Funding
Funding for this research was provided by:
Medical-Scientific Fund of the Mayor of the Federal Capital Vienna (APCOV26BGM)
- License Information
-
More Information
Article History
Received: 11 February 2025
Accepted: 4 June 2025
First Online: 1 July 2025
Declarations
:
: No relevant conflicts of interest are to declare in context with the present study. R. Lanzenberger received investigator-initiated research funding from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. J. Unterholzner received travel grants from Medice Pharma GmbH. T. Vanicek received speaker honoraria from Janssen. R. Frey served as consultant for Janssen and LivaNova and recieved speaker honoraria from Janssen and Lundbeck. D. Rujescu served as consultant for Janssen, received honoraria from Gerot Lannacher, Janssen and Pharmagenetix, received travel support from Angelini and Janssen, and served on advisory boards of AC Immune, Roche and Rovi.. V. Popper, A. Kautzky, M.B. Reed, M. Klöbl, A. Mühlberger, B. Spurny-Dworak, P. Stöhrmann, T.F. Wechsler declare no conflicts of interest.
